Aqua Bio Technology: Notice of extraordinary general meeting - Update on consideration to Jetcarrier sellers

23 Oct 2024 16:59 CEST

23.10.2024 16:59:29 CEST | Aqua Bio Technology ASA | Additional regulated
information required to be disclosed under the laws of a member state

An extraordinary general meeting of Aqua Bio Technology ASA (the "Company" or
"ABT") will be held on 13 November 2024 at 10:00 (CET) at Advokatfirmaet CLP DA,
Sommerrogata 13-15, 0255 Oslo. Please find attached the notice to the general
meeting. All documents to be treated at the general meeting will be made
available at the Company's website www.aquabiotechnology.com -
http://www.aquabiotechnology.com - http://www.aquabiotechnology.com.



Shareholders who wish to the attend the general meeting is requested to notify
the Company as set out in appendix 1 to the notice within 11 November 2024 at
16:00 (CET). In case of attendance by proxy, the proxy form (also included in
appendix 1 to the notice) is requested submitted to be received by the Company
within the same date.



Update on consideration to Jetcarrier sellers



As announced on 17 October 2024, the Company has entered into a share purchase
agreement with the shareholders of Jetcarrier AS to acquire all outstanding
shares in Jetcarrier AS (the "Acquisition"). Further, as announced on 18 October
2024, the Company has placed a conditional private placement of in total
38,363,470 new shares, each at a subscription price of NOK 3.00, for total gross
proceeds of approximately NOK 115.09 million (the "Private Placement"),
including NOK 57 million (equal to 19 million new shares) as partial settlement
of the purchase price under Acquisition.



In order to account for the issuance and listing of 5 million consideration
shares to the former shareholders of 3D Innovation Nordic AS, as announced in
the Company's stock exchange announcement on 29 August 2024, it has further been
agreed with the sellers of Jetcarrier AS that they shall convert an additional
NOK 3 million of the seller credit under the Acquisition into 1 million new
shares in the Company so that they maintain the desired ownership stake after
the completed Private Placement.



The board has therefore proposed issuance of these 1 million new shares to the
sellers of Jetcarriers AS, in addition to the 19 million new shares proposed
issued to such sellers, as previously announced.



For further information, please contact Jan Varming, CFO, telephone +47 90 83 90
76.



This information is subject of the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.

DISCLOSURE REGULATION

This information is subject of the disclosure requirements pursuant to section
of 5-12 of the Norwegian Securities Trading Act.

CONTACTS

* Jan Aas Varming, CFO, Aqua Bio Technology ASA, +47 908 39 076,
jan@aquabiotech.no

ABOUT AQUA BIO TECHNOLOGY ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.

ATTACHMENTS

Download announcement as PDF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/18295646/5153/Download%20announce
ment%20as%20PDF.pdf

241023 ABT - Innkalling EGF.pdf -
https://kommunikasjon.ntb.no/ir-files/17847556/18295646/5152/241023%20ABT%20-%20
Innkalling%20EGF.pdf

More information:
Access the news on Oslo Bors NewsWeb site

630227_241023 ABT - Innkalling EGF.pdf
630227_Download announcement as PDF.pdf